Idorsia Ltd To Discuss Daridorexant Phase 3 program published in The Lancet Neurology Call Transcript
Good day and thank you for standing by. Welcome to the daridorexant Phase III program published in The Lancet Neurology Conference Call. (Operator Instructions)
I must advise you that this conference call is being recorded today, Thursday, the 20th of January 2022. I would now like to hand over to your speaker for today, Mr. Andrew Weiss. Please go ahead, sir.
Thank you, operator. Good morning, good afternoon, everyone. This is Andrew speaking, Investor Relations at Idorsia. We're here to have a webcast to discuss the newly published results of daridorexant in the Lancet Neurology publication that was made available this morning.
With me on the call today are our CEO, Jean-Paul Clozel; our Chief Scientific Officer, Martine Clozel; our Head of Global Clinical Development, Guy Braunstein. And joining us afterwards for the Q&A, we will also have Simon Jose. Next slide.
As customary, we will be making forward-looking statements during this webcast
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |